The first phase 3 clinical trial of a molecularly targeted therapy for low grade IDH-mutant glioma showed positive results and opens the door to new possibilities for patients.
So the majority of low grade gliomas have I DH mutations. And the hope was that if you can inhibit mutant I DH, you can affect the growth of these tumors. But this has been a very controversial area and many people think that it's, it may not be successful. So the Indigo trial I think showed that I DH inhibitors can work in low grade gliomas with the I DH mutation. A second major area of advance is that these tumors tend to occur in young people in their thirties and forties in the prime of their lives. And the standard treatment is radiation and chemotherapy. But giving radiation to a young person means that year, a number of years later, they gonna inevitably get cognitive problems from the radiation. And one of the um positive aspects of the Indigo trial is that by using bide in it, you can delay the time when you need to treat these patients with radiation and chemotherapy. And so it delays a time when they might have to go undergo these toxic therapies and delay the time for them to have side effects.
